Lepu Scientech Medical Technology Shanghai Co 2291.HK · HKD
Health Care · HKEX · 🇭🇰 Hong Kong
14.48
+1.54%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lepu Scientech Medical Technology Shanghai Co
Its shares trade on HKEX under the ticker 2291.HK. It has been listed since 8 November 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥614.8m and net income of CN¥279.2m. At that date it held total assets of CN¥2.45bn and shareholders' equity of CN¥2.37bn.
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. operates as an investment holding company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-11-08. The firm operates primarily through two segments. The Occluder Business segment is mainly engaged in the research and development and sales of a series of interventional treatment series occluders for defective congenital heart disease. The Heart Valve Business segment is mainly engaged in the research and development of heart valve medical devices. The firm operates primarily in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 8 Nov 2022
- Employees
- 236
- Website
- scientechmed.com ↗
Leadership
Pay as last reported
- Ms. Juan ChenExecutive Chairman, General Manager, since 2021CN¥3.8m
- Mr. Xue QinChief Financial Officer, Deputy General Manager, Joint Company Secretary
- Mr. Yufeng HeChief Operating Officer, Deputy General Manager
- Ms. Xiani ZhangDeputy General Manager
- Mr. Kin Wai LiJoint Company Secretary
- Mr. Shan FuNon-Executive Director
- Ms. Yuxin ZhangNon-Executive Director, since 2021CN¥3.1m
- Mr. Guanfu ZhuNon-Executive Director
- Ms. Ka Lai ChanNon-Executive Independent DirectorCN¥67,000
- Mr. Junwei ZhengIndependent Non-Executive Director
- Mr. Yufeng ZhengNon-Executive Independent DirectorCN¥117,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Operates as an investment holding company with headquarters in Shanghai.
- Employs 236 full-time employees.
- Has two primary business segments: Occluder Business and Heart Valve Business.
Weaknesses
- Operates primarily in the domestic market, limiting international expansion.
- IPO occurred in 2022, indicating a relatively new public company.
- No mention of international market presence or global operations.
Opportunities
- Growth potential in the domestic health care market for congenital heart disease treatments.
- Expansion of heart valve medical device research and development.
- Potential for increased market share in interventional treatment series occluders.
Threats
- Dependence on the domestic market may limit growth opportunities.
- New competitors in the health care sector could impact market share.
- Regulatory changes in the health care industry may affect operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.